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Objective: To estimate the proportions of acute care inpa-
tient admissions and hospital days for schizophrenia pa-
tients in the Medicaid program that are attributable to
gaps in outpatient antipsychotic treatment and to calcu-
late the corresponding total health care costs of this care.
Methods: A series of multivariate regressions were per-
formed with statewide 2001–2003 California Medicaid
data to estimate the fraction of acute care hospital admis-
sions and hospital days for schizophrenia attributable to
gaps in antipsychotic medication treatment. This fraction
was then applied to national estimates of the number and
costsofinpatienttreatmentepisodesforpatientswithschizo-
phrenia in the national Medicaid program. Results: In the
United States, there are roughly 87 000 annual acute care
inpatientadmissions ofMedicaidpatientsforthetreatment
ofschizophrenia.Theseadmissionsincludeatotalofapprox-
imately930 000hospitaldaysatatotalcostof$806million.
Improving adherence to eliminate gaps in antipsychotic
medication treatment could lower the number of acute
care admissions by approximately 12.3% (95% confidence
interval [CI]: 11.7%–12.6%) and reduce the number of
inpatient treatment days by approximately 13.1% (CI:
9.8%–16.5%) resulting in a savings of approximately
$106 million (95% CI: $79.0 million–$133.0 million) in
inpatient care costs for the national Medicaid system.
Conclusions: Nonadherence to antipsychotic medication
treatment accounts for a considerable proportion of inpa-
tient treatment costs of Medicaid patients with schizophre-
nia. Improving continuity of antipsychotic medications
couldleadtosavingsbyreducingthefrequencyandduration
of inpatient treatment.
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Introduction
Nonadherence with antipsychotic medications is widely
believed to be an important proximal cause of hospital
admission in schizophrenia.
1,2 Randomized controlled
trials,
3 observational clinical studies,
2,4 and secondary
analyses of administrative data
5–8 all suggest that nonad-
herence with antipsychotic medications increases the risk
of hospital admission. In one cohort of patients with
chronic schizophrenia, for example, discontinuation of
antipsychotic medications approximately doubled the
risk of hospital readmission during the first 3 months fol-
lowing hospital discharge.
2
Despite steady declines in the length of inpatient
admissions,
9,10 hospital care continues to comprise a sub-
stantial proportion of overall health care costs of persons
with schizophrenia. Inpatient mental health treatment
has been estimated to account for over one-quarter of to-
tal US mental health expenditures.
11 This is approxi-
mately 3 times the costs of outpatient psychotropic
medications and more than the costs of outpatient serv-
ices provided by psychiatrists, psychologists, and social
workers combined.
11
The extent to which medication nonadherence contrib-
utes to the frequency, duration, and costs of acute care
hospital admissions for schizophrenia remain poorly un-
derstood.
4,12Inoneearlystudy,itwasestimatedthatmed-
ication discontinuation accounts for approximately 40%
of hospital costs of patients with schizophrenia during
a 2-year period following hospital discharge.
3 However,
thisfigurelikelyoverestimatesthecontributionofmedica-
tiondiscontinuationtoinpatientcostsincommunityprac-
tice because it was based on medication nonadherence
estimates from patients during their first few months fol-
lowinghospitaldischarge.Recentlydischargedinpatients
areknowntohaveanespeciallyhighriskofmedicationdis-
continuation
13,14 and hospital readmission.
15 The results
of this research are further limited because they are based
onasummaryofresultsfrompatientsinpublishedclinical
trials rather than the experiences of patients receiving
community care. Although lower antipsychotic adher-
ence
7 and gaps in antipsychotic treatment
6 have been
linked toincreased risk of inpatient admissionfor patients
in the community, the relative contribution of gaps in
maintenance antipsychotic treatment to the frequency
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173anddurationofacutecareinpatientuseandcostsremains
unknown.
Using econometric methods, we analyze the relation-
ship between gaps in antipsychotic medication and hos-
pital admission among California Medicaid (Medi-Cal)
recipients treated for schizophrenia in order to estimate
the fraction of hospital admissions and hospital days
attributable to gaps in antipsychotic medication. These
fractions are then applied to national estimates of acute
care hospital admissions and costs in the US Medicaid
system to derive the national number and cost of acute
care inpatient admissions for Medicaid schizophrenia
patients that are attributable to gaps in antipsychotic
medication treatment.
Methods
Sources of Data
IntheUnitedStates,Medicaidisthelargestpayerofcom-
munity hospital inpatient treatment for schizophrenia.
16
According to the 2004 Healthcare Cost and Utilization
Project,Medicaidwastheprimarypayerin54.5%ofcom-
munity hospital discharges with a principal diagnosis of
schizophrenia followed by Medicare (30.0%), private in-
surance (6.7%), other public insurance (4.7%), and no in-
surance(4.1%).BecauseoftheprominenceoftheMedicaid
programasapayerofinpatienttreatmentforschizophre-
nia, we draw on service use and pharmacy claims from
the largest Medicaid program, Medi-Cal (2001–2003)
17
tomodelassociationsbetweengapsinantipsychotictreat-
ment and hospital admission for the treatment of schizo-
phrenia. The data provide information on program
enrollment, inpatient and outpatient service use, specific
medications prescribed, date of prescription, and number
ofdaysofmedicationsupplied.Inthecurrentanalysis,we
focus on prescriptions of oral antipsychotic medications.
Two federal surveys were used to estimate the total
national distribution and costs of Medicaid-reimbursed
acute care hospital admissions for schizophrenia:
(1) the 1997 Client/Patient Sample Survey (CPSS) and
(2) the 2002 Survey of Mental Health Organizations
and General Hospital Mental Health Services, and Man-
aged Behavioral Health Organizations (SMHO).
The CPSS, which is organized by the Substance Abuse
and Mental Health Services Administration (SAMHSA),
collects data on the sociodemographic, diagnostic, and
service use characteristics of patients in organizations
in the United States that treat patients with mental dis-
orders. Within a probability sample of facilities, proba-
bility samples are selected of patients admitted during
a 1-month period. Patient-level data are weighted to cre-
ate national estimates of the total number of acute care
admissions and lengths of stay during a 1-year period.
10
In 1997, 2738 programs were sampled and 23 415
patients were sampled within these programs.
The SMHO, which is also organized by SAMHSA, is
a national survey completed by specialty mental health
organizations and nonfederal general hospitals treating
patients with mental disorders to determine national
costs of treatment episodes in each type of organization.
The 2002 SMHO inventory sought information on the
patient population and the nature of treatment episodes
at each facility in the United States.
18
Types of organizations surveyed in the CPSS and
SMHO include outpatient mental health clinics, psychi-
atrichospitals(privateandpublic), generalhospitals with
separate psychiatric services, Veterans Affairs medical
centers, federally funded community mental health cen-
ters, residential treatment centers, and other mental
health organizations including free-standing psychiatric
outpatient clinics, free-standing partial care organiza-
tions, and multiservice mental health organizations.
Cohort Selection for Medi-Cal Analyses
Medi-Cal recipients between age 18 and 64 years were
selected who had received at least 2 outpatient or 1 inpa-
tient claim for schizophrenia (International Classification
of Diseases [ICD]: 295).
19 Because of concern over the
consistency of the days supplied recorded for long-acting
antipsychotic medications,
5,6 patients receiving these
preparations were excluded from the analyses. Patients
with a diagnosis of bipolar disorder were also excluded
from the analyses as were patients who had a hospital ad-
mission for schizophrenia that lasted for more than 30
days. We focused on acute care (30 days) inpatient
admissions because they constitute the great majority
of inpatient treatment episodes for schizophrenia.
20
In addition, medication discontinuation may be more
closely associated with acute inpatient care
21 as com-
pared with long-term inpatient admissions, which are
presumably more closely related to treatment-resistant
clinical syndromes.
22 Patients under fee-for-service and
managed care financing were included in the analysis.
However, patients who filled no prescriptions for any
medications were excluded from the study cohort. This
eligibility criterion, which excluded 1.7% of our patient
sample, effectively removed patients within health plans
that do not report prescriptions.
Deﬁnition of Variables for Medi-Cal Analysis
On the basis of the antipsychotic prescription claims,
eachpatientdayinwhichthe patientwas eligibleforserv-
ices starting with the first mention of a schizophrenia di-
agnosis was considered as including either antipsychotic
treatment or no treatment. Antipsychotic treatment was
assumed to occur on each day with evidence of prescrip-
tion coverage and for 15 days following the termination
of the prescription coverage.
5–7 A sensitivity analysis was
conducted with a 30-day gap in the prescription record.
Days in which patients were hospitalized, other than the
admission day, were excluded from the analysis.
S. C. Marcus & M. Olfson
174Other day-level independent variables from the Medi-
Cal data include recipient age in years (18–25, 26–35,
36–45,46–64),sex,race(white,black,other),selectedcomor-
bid mental disorders as identified by a claim for the treat-
ment of substance use disorders (ICD-9: 291, 292,
303–305), anxiety disorders (300.0, 300.2, 300.3, or 308.3),
anddepressivedisorders(296.2,296.3,300.4,311)intheprior
90 days.
Acute care hospital admissions were defined to include
all new inpatient care episodes of 30-day duration or
shorter in which the primary diagnosis was schizophrenia
(295) or the second listed diagnosis was schizophrenia
and the primary diagnosis was another mental disorder
(290–294, 296–319). In addition, these short-term hospi-
tal admissions were partitioned by whether they lasted
1–14 days or 15–30 days to explore the possibility that
gaps in antipsychotic treatment influence a hospitaliza-
tion based on its subsequent length.
23
Analysis of Medi-Cal Data
Weused Medi-Cal data toconduct5 setsof analyses. The
first analysis determined the rate of inpatient admission
per 100 000 eligible person-days overall and stratified by
patient age-group, sex, and race/ethnicity among the
study patients. Second, among inpatient admissions,
the proportion with no use of antipsychotic medications
in the preceding 15 days was determined overall
and stratified by patient age-group, sex, race/ethnicity,
comorbid mental disorders, and length of inpatient
stay. Rao-Scott chi-square analyses were performed to
test for differences in rates across strata for each categor-
ical variable while accounting for the potential clustering
of hospitalizations within persons (a = 0.05, two tailed).
Third, a logistic regression analysis was performed with
individual patient days as the unit of observation to as-
sess the effects of antipsychotic medication non-use on
hospital admission controlling for demographic and
time-varying clinical factors previously described. Due
to the computational intensity required to conduct these
multivariate logistic models at the day level, we limited
the sample in this analysis to all patients with a schizo-
phreniahospitaladmissionbutonlyarandom5% sample
of patients who did not have a hospital admission.
Fourth, among the patients who were hospitalized, a lin-
ear model was used to assess the effects of antipsychotic
nonuse and other factors on the hospital length of stay.
The fifth set of analyses used methods of Miller et al
24 to
calculate the proportion of acute care hospital admis-
sions and the proportion of hospital days attributable
to medication nonuse. Using the beta coefficients from
the logistic model above along with the day-level data,
wecalculateapredictedprobabilityofhospitaladmission
oneachdayandthensumtheprobabilitiesacrossalldays
to obtain the total number of observed hospital admis-
sions. We then repeated this process assuming all days
were associated with antipsychotic treatment (ie, the beta
coefficient for nonadherence is forced to be 0) and
summed the predicted probabilities to obtain the pre-
dicted number of admissions assuming antipsychotic
treatment. The percentage change between the observed
and predicted number of acute care admissions is the
population-attributable percentage. Confidence intervals
(CIs) around the population-attributable percentage of
admissions were calculated by repeating the analysis by
summing the upper and lower 95% confidence intervals
for the predicted probabilities obtained from the logistic
model using maximum likelihood estimates. We then fol-
low the same technique applying the beta coefficients
from the linear model for length of stay for each admis-
sion. The process was repeated assuming all admissions
are preceded by antipsychotic medication use to calculate
a predicted length of stay for each admission. The pop-
ulation-attributable percentage of days is computed by
calculating the percentage change between the observed
and predicted number of days in the population. The ob-
servedandpredictednumberofdaysisthesum,acrossall
days, of the product of the appropriate predicted prob-
ability of admission and the predicted length of stay as
calculated above. The confidence interval around the cal-
culated population-attributable percentage of days was
obtained by computing SDs of each sum using Taylor
series linearization and using those values in a formula
proposed by the US Census Bureau to produce confi-
dence intervals around the percentage change.
25
National Volume and Costs of Acute Care Inpatient
Medicaid Admissions
Data from the 1997 CPSS were used to estimate the num-
ber of adult inpatient admissions of Medicaid patients
with schizophrenia that were 30 days or less in duration
and the total number of inpatient days in five types of
organizations: state and county mental hospitals, private
psychiatric hospitals, nonfederal general hospitals, med-
ical centers operated by the Department of Veterans
Affairs, and multiservice mental health organizations.
National estimates of the mean daily costs of inpatient
psychiatric care were derived from the 2002 SMHO for
all payers. Separate estimates from both surveys were de-
termined for each type of organization except multiser-
vice mental health organizations which were imputed
on the basis of state and county hospital data. Total in-
patient costs were determined by multiplying the total
number of Medicaid reimbursed inpatient days for pa-
tients with schizophrenia in each facility by the mean
daily expenditure for that type of organization. The hos-
pital services component of the Consumer Price Index
was used to inflate 2002 dollars to mid-year 2005 dollars
(18.1%).
26
The estimate of national inpatient acute care admis-
sionsattributable togaps inmedication usewas calculated
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admissions attributable to antipsychotic medication non-
use from the Medi-Cal analyses to the number of national
acute care inpatient admissions derived from the CPSS.
Similarly, the national number of inpatient days attrib-
utable to medication nonuse was computed by applying
the adjusted population fraction of inpatient days to the
national number of inpatient days derived from the
CPSS. The total inflation-adjusted inpatient costs were
calculated by multiplying the attributable number of
inpatient days by the mean daily costs within each type
of organization.
Results
Rates of Inpatient Admission
A total of 35 815 patients with schizophrenia were en-
tered into the Medicaid analysis. Approximately 2.2%
(n = 787) of these patients collectively accounted for
1028 schizophrenia inpatient admissions. The mean
length of stay of these admissions was 9.2 days (SD = 7.6
days). Overall, there were 23 161 428 eligible days corre-
sponding to 4.44 inpatient schizophrenia admissions per
100 000 person-days. Although the rate of schizophrenia
admissions tended to be higher for younger than older
patients, females than males, and members of racial
and ethnic minorities than white patients, none of these
differences were statistically significant (table 1).
Antipsychotic Treatment Prior to Inpatient Admission
Roughly one-third (36.6%) of acute care inpatient admis-
sions with schizophrenia occurred during gaps, (nonuse
days)intheantipsychoticmedicationprescriptionrecord.
In the bivariate analysis, patient age, race/ethnicity,
comoribid substance use disorder, and length of index
admission were each related to hospital admission during
agap. In the multivariate model, which controlled for pa-
tient age, sex, race, treatment of comorbid mental disor-
ders, and length of stay, no treatment with antipsychotic
medications within 15 days of the date of hospital admis-
sion was significantly more common among black than
white patients and patients with as opposed to without
comorbid substance use disorders. In addition, patients
whowere18–25yearsofageweresignificantlymorelikely
than those who were of age 46–65 years to have a gap in
antipsychotic medication use immediately prior to the
hospital admission (table 2).
Predictors of Inpatient Admission
In the analyses with days as the unit of observation, after
controlling for the potentially confounding effects of pa-
tient age, sex, race, and treatment of comorbid anxiety,
depressive, and substance use disorders, gaps in antipsy-
chotic medications were associated with a significant in-
crease in the odds of hospital admission (OR = 1.49,
95%CI:1.27–1.75)(table3).Inthismodel,comorbidsub-
stance use disorder and race/ethnicity other than black or
white were each related to acute care inpatient admission.
Attributable Acute Care Admissions and Inpatient Days
Adjusting for background patient characteristics, the
fraction of acute care inpatient admissions attributable
to not receiving antipsychotic medications was 12.3%
(95% CI: 11.7%–12.6%) and the fraction of inpatient
days attributable to not receiving antipsychotic medica-
tions was 13.1% (95% CI: 9.8%–16.5%) when a 15-day
gap in the prescription record was used. When a 30-
day gap was used, the attributable rates changed mod-
estly to 9.5% (95% CI: 9.0%–10.0%) of admissions and
10.2% (95% CI: 6.8%–13.7%) of days. In the following
Table1. RateofInpatientTreatmentforSchizophreniaper100 000EligiblePatient-DaysAmongOutpatientsTreatedforSchizophrenia
(N = 35 815)
Group Sample Size Eligible Days
Number of
Admissions
Rate of Inpatient Admission
per 100 000 Person-Days (95% CI)
Total 35 815 23 161 428 1028 4.44 (3.69–5.18)
Age, y
18–25 3233 1 901 443 134 7.05 (4.19–9.91)
26–35 6731 4 408 470 195 4.42 (3.14–5.71)
36–45 11 897 8 039 998 276 3.43 (2.30–4.56)
46–64 13 954 8 811 517 423 4.80 (3.40–6.20)
Sex
Male 20 982 13 670 688 563 4.12 (3.13–5.11)
Female 14 833 9 490 740 465 4.90 (3.76–6.40)
Race/ethnicity
White 18 628 12 374 483 493 4.00 (3.06–4.94)
Black 6375 3 963 816 180 4.54 (2.96–6.13)
Other 10 806 6 820 478 353 5.18 (3.55–6.80)
Note: Data from 2001–2003 Medi-Cal files.
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estimates.
Hospital Admissions
According to the 1997 CPSS, there are an estimated
86 878 annual acute care hospital admissions and total
930 062 inpatient days provided to Medicaid-financed
patients for the treatment of schizophrenia in the United
States. Nearly three-quarters (74.6%) of these admissions
were to nonfederal general hospitals. The remainder of
the admissions was distributed among multiservice men-
tal health organizations (12.1%), private psychiatric hos-
pitals (10.5%), state and county mental hospitals (2.8%),
and medical centers operated by the Department of
Veterans Affairs (0.01%).
The total cost of these inpatient admissions is approx-
imately $806 million. This estimate is derived by applying
the 2002 SMHO mean daily costs of inpatient treatment
for each organization, adjusted for inflation, to the esti-
mated number of inpatient days in that organization.
Applying the adjusted attributable fraction of inpa-
tient admissions due to gaps in antipsychotic treatment
(12.3%, 95% CI: 11.7%–12.6%) to the national estimate
of admissions yields 10 686 (95% CI: 10 165–10 947) an-
nual acute care hospital admissions attributable to gaps
in antipsychotic treatment. Applying the adjusted attrib-
utable fraction of inpatient days (13.1%, 95% CI: 9.8%–
16.5%) yields 121 838 inpatient days and an inpatient
cost of approximately $106 million (95% CI: $79.0
million–$133.0 million) attributed to gaps in treatment.
Discussion
During the course of 1 year, there are roughly 87 000
acute care inpatient admissions of patients with schizo-
phrenia in the Medicaid program. The cost of these
admissions is approximately $800 million. At the time
of admission, we estimate that roughly 30 000 or slightly
more than one-third of the acute care admissions for
schizophrenia are not being treated with antipsychotic
Table 2. Proportion of Acute Care Inpatient Admissions for Patients With Schizophrenia That Occur During a Gap in Antipsychotic
Treatment (N = 1028)
Group
Percentage of Admissions
During a Gap in
Antipsychotics v
2 df P
a OR (95% CI)
b
Total (N = 1028) 36.6
Age, y 15.3 9 .002
18–25 (n = 134) 42.5 (reference)
26–35 (n = 195) 46.7 1.13 (0.69–1.84)
36–45 (n = 276) 37.0 0.77 (0.48–1.23)
46–64 (n = 423) 29.8 0.58 (0.36–0.95)
Sex 0.5 1 0.47
Male (n = 563) 35.4 (reference)
Female (n = 465) 38.1 1.15 (0.85–1.58)
Race/ethnicity 6.3 2 .044
White (n = 495) 32.5 (reference)
Black (n = 180) 45.5 1.62 (1.10–2.40)
Other (n = 353) 37.5 1.22 (0.85–1.77)
Treatment of comorbid substance use disorder 10.8 1 .001
Present (n = 219) 46.6 1.62 (1.10–2.21)
Absent (n = 809) 33.9 (reference)
Treatment of comorbid depressive disorder 0.04 1 .84
Present (n = 139) 37.4 .91 (0.60–1.38)
Absent (n = 889) 36.4 (reference)
Treatment of comorbid anxiety disorder 0.02 1 .89
Present (n = 56) 37.5 0.92 (0.50–1.72)
Absent (n = 972) 36.5 (reference)
Length of inpatient stay, days 8.9 1 .003
1–14 (n = 788) 37.9 (reference)
15–30 (n = 240) 32.1 0.88 (0.63–1.23)
Note: Data from 2001–2003 Medi-Cal files. Gap in antipsychotic treatment defined as a period of longer than fifteen days beyond the
end of the last supplied antipsychotic medications.
aThe P values are derived from bivariate analyses.
bOdds ratios (ORs) are derived from a multivariable analysis of a single logistic model with antipsychotic gap as the dependent variable
and the variables in all rows as independent variables.
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number of these admissions gaps in antipsychotic medi-
cation, rather than other patient characteristics, account
for the inpatient admission. Consistent use of antipsy-
chotic treatment could result in a savings of approxi-
mately $106 million in acute care inpatient Medicaid
care costs. Continuous use of antipsychotic medications
could also decrease the costs of emergency department
services, crisis care, and other relapse-related mental
health services in the community treatment of schizo-
phrenia.
27
The proportion of acute care inpatient admissions that
were preceded by antipsychotic medication nonuse
(36.6%) is in the low end of the range of previously
reported rates (28%–72%) using a variety of different
measures of medication nonuse.
21,28,29 High rates of
medication nonuse or nonadherence prior to inpatient
admission highlight problems in the continuity of phar-
macological treatment. In practice, clinicians may not be
aware of patient problems in this area. In 1 study, the
medication electronic monitoring system, which is a cap
that detects each pill bottle opening, detected significant
antipsychotic medication non-adherence in 12 of 25
schizophrenia patients while clinicians detected non-
adherence in none of the patients.
30
Inpatientepisodesoccurringduringtreatmentcontinu-
ity gaps were especially evident for patients with sub-
stance use disorders. It is possible that deficits in self-
care, disruptive behaviors, housing instability, financial
crises, and other functional disturbances related to sub-
stance use help to explain the connection between sub-
stance use and antipsychotic nonadherence among
inpatient admissions.
31–33 Treatment of these comorbid
substance use disorders and careful outpatient vigilance
of treatment continuity in minority populations might
reduce gaps in antipsychotic medication treatment, sub-
sequent hospital admissions, and cost of care.
Among admitted patients, those who were treated for
comorbid substance use, depressive, or anxiety disorders
prior to their inpatient admission tended to have signif-
icantly shorter inpatient stays than patients who had not
been treated for these comorbid disorders. Although the
clinical basis for these differences in length of stay is un-
known, comorbid substance use disorders have been pre-
viously associated with shorter inpatient treatment of
schizophrenia.
34,35 It has been hypothesized that sub-
stance use may temporarily amplify symptoms of schizo-
phrenia in a manner that permits faster stabilization
during short-term admission.
36 It is conceivable that
comorbid anxiety and depressive disorders function in
a similar manner.
The medication possession ratio is the most commonly
used method for measuring medication use in research
with administrative claims data.
5–8 Each subject is
assigned a ratio of the total number of days supplied
of medication to the number of days during the study pe-
riod.Alimitationofthisapproachisthatitdoesnotmea-
sure medication availability at a fixed point in time.
35 By
contrast, the method employed in the current study cap-
tures short-term variations in medication availability and
thereby provides a means of temporally examining the
effect of medication availability on the risk of hospital
admission.
The study findings should be viewed in the context of
several methodological limitations. First, although phar-
macyclaimsmeasurepsychotropicmedicationutilization
with reasonable accuracy,
36,37 prescription records are
only a proxy for actual pill-taking behavior. A direct
measure of medication use would have been preferable
to relying on prescription billing records. Slightly differ-
ent results were obtained when the medication gap was
selected at 30 rather than 15 days in medication supply.
Second, we assume that all patients with schizophrenia
not prescribed antipsychotic medications are ‘‘medica-
tion nonadherent.’’ However, some patients with schizo-
phrenia are not prescribed antipsychotic medications,
38
and others may be experiencing side effects or other
tolerability issuesthat havenotbeen addressed.For these
Table3. PredictorsofInpatientAdmissionandLengthofStayfor
the Treatment of Schizophrenia at the Day Level
Predictor
Admissions,
OR (95% CI)
(N = 1028
Admissions)
Length of
Stay b, P
(N = 1 292
697 Days)
Nonuse of anitpsychotics 1.49 (1.27–1.75) 0.51, P = .31
Comorbid mental disorders
Substance use disorder
(absent)
3.61 (2.96–4.41) 3.73, P < .0001
Anxiety disorder
(absent)
1.27 (0.94–1.73) 2.09, P = .02
Depressive disorder
(absent)
1.26 (.98–1.61) 2.87, P < .0001
Race (white)
Black 1.04 (.82–1.31) 1.76, P = .02
Other 1.30 (1.02–1.66) 0.29, P = .68
Sex (male)
Female 1.16 (.94–1.42) 0.72, P = .29
Age (y) 1.00 (.99–1.01) 0.02, P = .47
Note: Data from 2001–2003 Medi-Cal files. Results of
admissions analysis in the first data column are presented as
odds ratios (OR) and confidence intervals (CIs) from a logistic
regression with inpatient admission for acute care hospital
treatment of schizophrenia as the dependent variable. Results of
length of stay analysis in the second data column are beta (b)
coefficients and associated P values from a linear regression of
hospital admission days with length of inpatient stay as the
dependent variable. Reference groups are listed in parentheses.
The adjusted population-attributable fraction of admissions
related to gaps in antipsychotic treatment was 12.1%, and the
attributable fraction of inpatient days related to gaps in
medication was 13.1%. See text for derivation of attributable
fractions.
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tion availability than adherence or continuation. Third,
Medicaid data provide no information concerning sev-
eral factors, such as illness awareness, the therapeutic al-
liance, family support, or monitoring of medications that
may exert influence on medication availability. Fourth,
the analyses were limited to acute care hospitalizations
and may not generalize to long-term admissions. Longer
inpatient admissions presumably tend to involve patients
who remain symptomatic despite various medication tri-
als and may not therefore bear the same relationships to
medication nonadherence. Fifth, the analysis assumes
that Medicaid patients in California share similar pat-
terns of medication treatment and hospital admission
with patients from other state Medicaid programs. Cal-
ifornia accounts for a substantial proportion (14.4%) of
all Medicaid enrollees
39 and ranks in the middle (twenty-
fifth) among states in per capita Medicaid spending,
40
though it has a relatively low per capita rate of mental
health inpatient admissions.
41 A recent assessment con-
ducted by the National Alliance on Mental Illness deter-
mined that the California state system together with 36
other state systems have moderate problems with access
to psychiatric inpatient care.
42 This suggests that the
quality of schizophrenia treatment and use of inpatient
services under Medi-Cal broadly resembles patterns
across the state Medicaid programs and supports the
useof Medi-Cal patientsasa proxyforthe nationalMed-
icaid experience. However, little is known about the nar-
rower issue of state-to-state variation in relationships
between antipsychotic nonadherence and inpatient ad-
mission among schizophrenia patients in the Medicaid
program. Sixth, our cost estimates further assume that
the duration and volume of acute care hospital admis-
sions for schizophreniahave remained relatively constant
since 1997. The average length of stay in US short-stay
nonfederal hospitals for discharges with a first listed di-
agnosis of schizophrenia declined slightly between 1997
(11.9 days) and 2004 (10.8 days), while the number of
schizophrenia discharges has increased from 262 000 in
1997 to 331 000 in 2004.
43,44 Seventh, the Taylor series
confidence intervals surrounding the total inpatient costs
associated with gaps in antipsychotic treatment may un-
derestimate the extent of uncertainty because they do not
fully incorporate the effects of the admissions’ estimate
on the days estimate and, furthermore, no error estimates
are available from the national survey data or the Con-
sumerPriceIndex.Finally,theMedi-Calanalysesbutnot
the national projections exclude the small proportion of
schizophrenia patients receiving depot antipsychotic
medications. Depot is a widely recognized pharmaco-
logical approach to the treatment of medications non-
adherence in schizophrenia.
45
Gaps in antipsychotic medication treatment appear to
make a meaningful contribution to the national costs of
acute care inpatient treatment of schizophrenia patients
in the Medicaid program. Enhancing continuity of
antipsychotic treatment, through improvements in be-
havioral and psychosocial interventions, medication tol-
erability, and drug delivery systems, has the potential to
reduce the economic as well as the human costs of relapse
and hospital admission in schizophrenia.
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